Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG39093

DNAJB12 Knockout MES-OV Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Ovary

  • Disease:

    Ovarian serous cystadenocarcinoma

The DNAJB12 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout pool derived from the MES-OV ovarian endometrioid carcinoma cell line, targeting the ERAD co-chaperone DNAJB12. DNAJB12, activated by ER stress via ATF6/IRE1, complexes with Hsp70 and VCP/p97 to retrotranslocate misfolded proteins for proteasomal degradation. This loss-of-function model is ideal for studying ER stress, UPR, and protein aggregation in cancer and neurodegeneration research. Applications include Western blotting for BiP/CHOP, RT-qPCR of UPR targets, immunofluorescence for aggregates, and cell viability assays. For inquiries, please contact Ascent Research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    MES-OV

    Sex of Donor

    Female

    Age

    53 years

    Derived From Site

    Ascites

    Gene Name

    DNAJB12

    Gene Identifier

    NCBI Gene ID 54788

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    McCoy's 5A

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The DNAJB12 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian endometrioid carcinoma cell line. They feature targeted disruption of the DNAJB12 gene, which encodes an ER-associated degradation (ERAD) co-chaperone. The polyclonal editing generates a heterogeneous loss-of-function pool, enabling robust genotype-phenotype studies without clonal isolation. This product offers a versatile system for investigating DNAJB12-dependent processes in an ovarian cancer epithelial context.

MES-OV is an epithelial cancer cell line originating from ovarian endometrioid carcinoma. It serves as a clinically relevant model for studying ovarian cancer biology, including tumor progression and stress responses. In these cells, the DNAJB12 knockout allows dissection of how ERAD co-chaperone activity impacts cancer cell protein homeostasis and survival signaling.

DNAJB12 is a J-domain co-chaperone that collaborates with Hsp70 to recognize and retrotranslocate misfolded ER proteins via the ERAD pathway. Its activity is modulated by upstream ER stress transducers ATF6 and IRE1, which initiate UPR signaling. DNAJB12 forms complexes with Hsp70 and VCP/p97, extracting substrates from the ER membrane and targeting them for proteasomal degradation. Loss of DNAJB12 disrupts this clearance mechanism, leading to accumulation of misfolded proteins and chronic ER stress.

In MES-OV cells, DNAJB12 knockout likely impairs ERAD, heightening ER stress and UPR activation. Since ovarian cancer cells often rely on robust protein folding to sustain proliferation, this deficiency may expose vulnerabilities in quality control networks. Additionally, DNAJB12 is linked to neurodegeneration, including Parkinson??s disease, making this model valuable for exploring ERAD dysfunction across cancer and neurobiology.

This polyclonal knockout is optimized for ER stress profiling via Western blot (BiP, CHOP) and RT-qPCR of UPR targets. Researchers can assess protein aggregation by immunofluorescence and measure cell viability under chemical ER stress. The model also facilitates studies of DNAJB12 interactions with Hsp70, VCP/p97, and the proteasome, and supports drug screening for ERAD modulators. For further details or to order this product, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)